FACS analyses confirmed that LDN-193189 decreased the size of the CD133+ population (Figure 5F), suggesting that the ALK2/3 inhibitor could decrease the cells with TICs in MBs. This evidence concerns the gene ACVR1 and Mobius syndrome.